Recombinase Brec1 trend-setting for future HIV therapy

(Technische Universität Dresden) Researchers at the Medical Faculty of the Technische Universität Dresden and the Heinrich Pette Institute, Leibniz Institute for Experimental Virology succeeded in developing a designer recombinase (Brec1) that is capable of specifically removing the provirus from infected cells of most primary HIV-1 isolates. The results have now been published in the renowned Journal Nature Biotechnology.